At this moment, representatives of the Ministry of Health are participating in an online interview to update the epidemiological scenario of covid-19 and the balance of delivery of medicines and strategic supplies to combat the disease.
Watch live Research shows that covid-19 is also a vascular disease
Researchers from the Pontifical Catholic University of Paraná (PUCPR) proved that covid-19 is not only a lung disease, but it is also a vascular disease. A study carried out with post-mortem samples, authorized by the relatives of patients who died due to covid-19, showed that they had lesions in the cell that lines the blood vessel, with the possibility of causing thrombi and leading to death. Patients with a mean age of 75 years and with comorbidities such as arterial hypertension, diabetes and obesity were analyzed. read more
Anvisa evaluates non-clinical studies of covid-19 vaccine
The National Health Surveillance Agency (Anvisa) started the analysis of the “first data package” of the covid-19 vaccine under development by the University of Oxford and by the Anglo-Swedish company AstraZeneca.
In a note, the regulatory agency says that this does not mean that a conclusion can already be reached on the quality, safety and efficacy of the vaccine, as much data still needs to be analyzed. read more
Anvisa accelerates analysis of registration of vaccines against covid-19
São Paulo State signs contract with Sinovac and provides vaccine for December
The vaccine is being developed by the Chinese pharmaceutical company Sinovac in partnership with the Butantan Institute and is in phase 3 of human testing. This phase 3 of human testing tests the vaccine’s effectiveness and has been taking place in Brazil since July, with 13,000 volunteers in the health field.
The expectation of the São Paulo government is that the vaccination of these volunteers will be closed by October 15. If the tests prove the vaccine’s effectiveness, it will need an approval from Anvisa before being made available for vaccination in Brazil. read more